FYCOMPA
What it isSelective non-competitive AMPA receptor antagonist; focal and generalized seizures.
Why this oneA mechanism no other antiepileptic uses, so it adds where others have failed, and it is once daily at night.
What limits itSerious psychiatric and behavioral reactions, including aggression. Dizziness; CYP3A4-dependent.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Partial-onset seizures (monotherapy or adjunctive) | >=4 yr | 2 mg QHS | 8-12 mg QHS | 12 mg QD |
| Primary generalized tonic-clonic seizures (adjunctive) | >=12 yr | 2 mg QHS | 8 mg QHS | 12 mg QD |
Titration Increase by 2 mg/day no more than weekly (no more than every 2 weeks in elderly).
Renal Mild: no adjustment. Moderate: use with caution, consider slower titration. Severe or hemodialysis: not recommended.
Hepatic Mild: max 6 mg/day. Moderate: max 4 mg/day. Severe: not recommended.
With moderate/strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, oxcarbazepine): start 4 mg QHS.
Pregnancy No adequate human data; animal studies show developmental toxicity - may cause fetal harm.
Lactation No human data; present in rat milk - weigh benefits against risk.
⚠ BOXED WARNING
Cost, est. cash$300–$2,500/month
Generic entry2025
Legacy pregnancy categoryC
Defining liabilitySedation, dizziness and agent-specific rash, behavioral, hepatic, hematologic or teratogenic toxicity.

Open Perampanel in the interactive console ↗

